UY38075A - Composiciones anticonceptivas con efectos cardiovasculares reducidos - Google Patents
Composiciones anticonceptivas con efectos cardiovasculares reducidosInfo
- Publication number
- UY38075A UY38075A UY38075A UY38075A UY38075A UY 38075 A UY38075 A UY 38075A UY 38075 A UY38075 A UY 38075A UY 38075 A UY38075 A UY 38075A UY 38075 A UY38075 A UY 38075A
- Authority
- UY
- Uruguay
- Prior art keywords
- thromboembolism
- cardiovascular effects
- reduced
- reduced risk
- reduced cardiovascular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un método anticonceptivo con efectos cardiovasculares reducidos, tal como riesgo reducido de tromboembolismo, tal como riesgo reducido de tromboembolismo venoso (TEV) y riesgo reducido de tromboembolismo aórtico (TEA). El método de la invención comprende administrar a un mamífero hembra una cantidad eficaz de un componente estetrol en combinación con un componente progestagénico. El método tiene un perfil favorable para el tromboembolismo en comparación con los métodos actualmente disponibles que emplean anticonceptivos de la llamada segunda, tercera o cuarta generación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18155571 | 2018-02-07 | ||
| EP18160586 | 2018-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY38075A true UY38075A (es) | 2019-10-01 |
Family
ID=65278388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY38075A UY38075A (es) | 2018-02-07 | 2019-02-07 | Composiciones anticonceptivas con efectos cardiovasculares reducidos |
Country Status (17)
| Country | Link |
|---|---|
| EP (2) | EP3749327A1 (es) |
| JP (2) | JP2021513507A (es) |
| KR (1) | KR20200118464A (es) |
| CN (2) | CN115429806A (es) |
| AU (1) | AU2019219070A1 (es) |
| CA (2) | CA3178181A1 (es) |
| CL (1) | CL2020002017A1 (es) |
| EC (1) | ECSP20054822A (es) |
| GE (1) | GEP20227407B (es) |
| IL (1) | IL276584B1 (es) |
| JO (1) | JOP20200169A1 (es) |
| MA (1) | MA51733A (es) |
| PH (1) | PH12020500601A1 (es) |
| SG (1) | SG11202007163WA (es) |
| UA (1) | UA126746C2 (es) |
| UY (1) | UY38075A (es) |
| WO (1) | WO2019154899A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3701944B1 (en) | 2015-06-18 | 2021-12-08 | Estetra SRL | Orodispersible dosage unit containing an estetrol component |
| CA2988362C (en) | 2015-06-18 | 2022-07-19 | Mithra Pharmaceuticals S.A. | Orodispersible tablet containing estetrol |
| CN116077454A (zh) | 2015-06-18 | 2023-05-09 | 埃斯特拉有限责任公司 | 含雌四醇组分的口腔分散剂量单位 |
| DK3310345T3 (da) | 2015-06-18 | 2021-05-25 | Estetra Sprl | Orodispersibel tablet indeholdende estetrol |
| KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| TW202203935A (zh) * | 2020-04-16 | 2022-02-01 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| WO2022248733A1 (en) | 2021-05-28 | 2022-12-01 | Neuralis Sa | Use of estetrol in treatment of respiratory infection diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
| WO2002094279A1 (en) * | 2001-05-23 | 2002-11-28 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception |
| EP1535618A1 (en) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| WO2010133314A1 (de) * | 2009-05-22 | 2010-11-25 | Bayer Schering Pharma Aktiengesellschaft | Arzneimittel zur oralen verabreichung, enthaltend mindestens ein estrogen und/oder mindestens ein gestagen und mindestens einen probiotischen bakterien-stamm |
| WO2012055840A1 (en) * | 2010-10-28 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders |
| EA032306B1 (ru) * | 2013-12-12 | 2019-05-31 | Донеста Байосайенс Б.В. | Орально распадающаяся твердая фармацевтическая единица дозирования, содержащая эстетрольный компонент, ее применение и способ получения |
| CA3041016C (en) | 2016-10-28 | 2023-09-05 | Estetra Sprl | Method for the management of dysmenorrhea and menstrual pain |
| KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
-
2019
- 2019-02-07 EP EP19703103.2A patent/EP3749327A1/en active Pending
- 2019-02-07 CN CN202211257175.1A patent/CN115429806A/zh active Pending
- 2019-02-07 IL IL276584A patent/IL276584B1/en unknown
- 2019-02-07 EP EP22199066.6A patent/EP4140489A1/en active Pending
- 2019-02-07 AU AU2019219070A patent/AU2019219070A1/en active Pending
- 2019-02-07 SG SG11202007163WA patent/SG11202007163WA/en unknown
- 2019-02-07 CA CA3178181A patent/CA3178181A1/en active Pending
- 2019-02-07 UY UY38075A patent/UY38075A/es unknown
- 2019-02-07 KR KR1020207025456A patent/KR20200118464A/ko not_active Application Discontinuation
- 2019-02-07 GE GEAP201915414A patent/GEP20227407B/en unknown
- 2019-02-07 WO PCT/EP2019/052980 patent/WO2019154899A1/en active Search and Examination
- 2019-02-07 CA CA3089804A patent/CA3089804A1/en active Pending
- 2019-02-07 JP JP2020538823A patent/JP2021513507A/ja active Pending
- 2019-02-07 MA MA051733A patent/MA51733A/fr unknown
- 2019-02-07 UA UAA202005421A patent/UA126746C2/uk unknown
- 2019-02-07 JO JOP/2020/0169A patent/JOP20200169A1/ar unknown
- 2019-02-07 CN CN201980012248.0A patent/CN111683664A/zh active Pending
-
2020
- 2020-07-13 PH PH12020500601A patent/PH12020500601A1/en unknown
- 2020-07-31 CL CL2020002017A patent/CL2020002017A1/es unknown
- 2020-09-04 EC ECSENADI202054822A patent/ECSP20054822A/es unknown
-
2023
- 2023-09-28 JP JP2023168039A patent/JP2024009834A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3178181A1 (en) | 2019-08-15 |
| AU2019219070A1 (en) | 2020-09-24 |
| KR20200118464A (ko) | 2020-10-15 |
| JP2024009834A (ja) | 2024-01-23 |
| CN115429806A (zh) | 2022-12-06 |
| CL2020002017A1 (es) | 2020-12-04 |
| GEP20227407B (en) | 2022-08-25 |
| ECSP20054822A (es) | 2020-12-31 |
| JP2021513507A (ja) | 2021-05-27 |
| CN111683664A (zh) | 2020-09-18 |
| SG11202007163WA (en) | 2020-08-28 |
| EP4140489A1 (en) | 2023-03-01 |
| WO2019154899A1 (en) | 2019-08-15 |
| TW202011967A (zh) | 2020-04-01 |
| UA126746C2 (uk) | 2023-01-18 |
| IL276584B1 (en) | 2024-06-01 |
| JOP20200169A1 (ar) | 2020-07-07 |
| EP3749327A1 (en) | 2020-12-16 |
| IL276584A (en) | 2020-09-30 |
| CA3089804A1 (en) | 2019-08-15 |
| MA51733A (fr) | 2020-12-16 |
| PH12020500601A1 (en) | 2021-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38075A (es) | Composiciones anticonceptivas con efectos cardiovasculares reducidos | |
| DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| CO2019000672A2 (es) | Procedimiento de tratamiento de dismenorrea y dolor menstrual | |
| CL2020002252A1 (es) | Formulación oftálmica. | |
| MX2019003364A (es) | Composiciones oftalmicas que comprenden ciclosporina. | |
| CL2020000220A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| PE20151947A1 (es) | Reduccion de la respuesta proinflamatoria | |
| CL2017001964A1 (es) | Encapsulado de agentes activos de alta potencia. | |
| AR101236A1 (es) | Composiciones para el cuidado oral | |
| CO2020005366A2 (es) | Composición plaguicida que contiene tidiazurón y ácido poliglutámico | |
| BR112017010933A2 (pt) | composição farmacêutica | |
| CO2021004934A2 (es) | Composiciones y métodos para tratar retinitis pigmentosa | |
| MX2017009929A (es) | Composiciones y métodos para metabolismo muscular mejorado. | |
| CL2019000174A1 (es) | Composición vaginal que comprende una combinación de estrógeno y vitamina d. | |
| AR114357A1 (es) | Composiciones anticonceptivas con efectos cardiovasculares reducidos | |
| CL2021001096A1 (es) | Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196) | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac | |
| CL2020000221A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| EA201891752A2 (ru) | Фармацевтическая композиция для улучшения состояния при хронической почечной недостаточности или предотвращения ее прогрессирования | |
| MX2019014988A (es) | Uso de canagliflozina para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii. | |
| CL2021003532A1 (es) | Método para estabilizar el ph de una composición acuosa que comprende un fármaco. | |
| CO2021012209A2 (es) | Composición para cuidado oral | |
| EA202091811A1 (ru) | Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы | |
| BR112017016429A2 (pt) | ?vacina, uso de um antígeno de lawsonia intracellularis não vivo, e, método para reduzir o impacto negativo no ganho de peso diário médio (adwg) de um porco associado com infecção subclínica com lawsonia intracellularis? | |
| BR112016006139A2 (pt) | componente elétrico e método para fabricar o mesmo |